Pathogen-specific AAPC
Pathogen-specific AAPC Uses, Dosage, Side Effects, Food Interaction and all others data.
Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was developed using domains of viral structural proteins and a polyprotein protease. Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these engineered minigenes to express viral proteins, modify artificial antigen presenting cells (aAPC), and activate T-cells.
As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
| Trade Name | Pathogen-specific AAPC |
| Generic | Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine |
| Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine Other Names | aAPC, artificial antigen -Pathogen-specific vaccine, Pathogen-specific aAPC |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Pathogen-specific AAPC
